Table 1. SSTR2 targeted recent and active clinical trials for small cell lung cancer and high grade neuroendocrine carcinomas.
| Trial name | Target | Payload | Trial status | Identifier | Last update |
|---|---|---|---|---|---|
| Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and other Advanced Neuroendocrine Carcinomas | SSTR2 (peptide agonist) | Rhenium-188 | Withdrawn | NCT02030184 | 2017 |
| PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers including Neuroendocrine and Small Cell Lung Cancers | SSTR2 (peptide agonist) | DM-1 | Recruiting | NCT02936323 | 2019 |
| Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 with Companion Imaging 68G-OPS202 PET/CT in Previously Treated Subjects with locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) | SSTR2 (peptide antagonist) | 177Lu | Recruiting | NCT03773133 | 2019 |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive Stage Small Cell Lung Cancer | SSTR2 (peptide agonist) | 177Lu | Active, not recruiting | NCT03325816 | 2018 |
| A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours | SSTR2 (peptide agonist) | 177Lu | Recruiting | NCT01876771 | 2017 |